Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Nature

Volumn 496, Issue 7446, 2013, Pages 469-476

  Liao, Hua Xin ^a,b   Lynch, Rebecca ^c   Zhou, Tongqing ^c   Gao, Feng ^a,b   Munir Alam, S ^a,b   Boyd, Scott D ^d   Fire, Andrew Z ^d   Roskin, Krishna M ^d   Schramm, Chaim A ^e   Zhang, Zhenhai ^e   Zhu, Jiang ^c   Shapiro, Lawrence ^c,e   Mullikin, James C ^f,g   Gnanakaran, S ^h   Hraber, Peter ^h   Wiehe, Kevin ^a,b   Kelsoe, Garnett ^a,b   Yang, Guang ^a,b   Xia, Shi Mao ^a,b   Montefiori, David C ^a,b   Parks, Robert ^a,b   Lloyd, Krissey E ^a,b   Scearce, Richard M ^a,b   Soderberg, Kelly A ^a,b   Cohen, Myron ⁱ   Kamanga, Gift ^j   Louder, Mark K ^c   Tran, Lillian M ^c   Chen, Yue ^a,b   Cai, Fangping ^a,b   Chen, Sheri ^a,b   Moquin, Stephanie ^c   Du, Xiulian ^c   Gordon Joyce, M ^c   Srivatsan, Sanjay ^c   Zhang, Baoshan ^c   Zheng, Anqi ^c   Shaw, George M ^k   Hahn, Beatrice H ^k   Kepler, Thomas B ^l   Korber, Bette T M ^h   Kwong, Peter D ^c   Mascola, John R ^c   Haynes, Barton F ^a,b   Becker, Jesse ^f   Benjamin, Betty ^f   Blakesley, Robert ^f   Bouffard, Gerry ^f   Brooks, Shelise ^f   Coleman, Holly ^f   Dekhtyar, Mila ^f   Gregory, Michael ^f   Guan, Xiaobin ^f   Gupta, Jyoti ^f   Han, Joel ^f   Hargrove, April ^f   Ho, Shi Ling ^f   Johnson, Taccara ^f   Legaspi, Richelle ^f   Lovett, Sean ^f   Maduro, Quino ^f   Masiello, Cathy ^f   Maskeri, Baishali ^f   McDowell, Jenny ^f   Montemayor, Casandra ^f   Mulliki, James ^f   Park, Morgan ^f   Riebow, Nancy ^f   Schandler, Karen ^f   Schmidt, Brian ^f   Sison, Christina ^f   Stantripop, Mal ^f   Thomas, James ^f   Thomas, Pam ^f   Vemulapalli, Meg ^f   Young, Alice ^f   more..

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d STANFORD UNIVERSITY   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^h LOS ALAMOS NATIONAL LABORATORY   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l BOSTON UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CH103 FAB ANTIBODY; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY; COEVOLUTION; CRYSTAL STRUCTURE; DATA ACQUISITION; MATURATION; PROTEIN; VACCINATION; VIRUS;

ANTIBODY RESPONSE; ANTIBODY STRUCTURE; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; BINDING SITE; CD4+ T LYMPHOCYTE; DISEASE TRANSMISSION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; VACCINATION; VIRUS GENE; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

AFRICA; AIDS VACCINES; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; CELL LINEAGE; CELLS, CULTURED; CLONE CELLS; CROSS REACTIONS; CRYSTALLOGRAPHY, X-RAY; EPITOPES; EVOLUTION, MOLECULAR; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NEUTRALIZATION TESTS; PHYLOGENY; PROTEIN STRUCTURE, TERTIARY;

AFRICA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84876797103     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12053     Document Type: Article

References (71)

1. Walker, L. M. et al. Broad and potent neutralizing antibodies froman African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
2. Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
3. Burton, D. R., Poignard, P., Stanfield, R. L. & Wilson, I. A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337, 183-186 (2012).
4. Kwong, P. D. & Mascola, J. R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37, 412-425 (2012).
5. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
6. Wu, X. et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593-1602 (2011).
7. Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817 (2010).
8. Sattentau, Q. J.&McMichael, A. J.Newtemplates for HIV-1antibody-based vaccine design. F1000 Biol. Rep. 2, 60 (2010).
9. Stamatatos, L. HIV vaccine design: the neutralizing antibody conundrum. Curr. Opin. Immunol. 24, 316-323 (2012).
10. Haynes, B. F. et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906-1908 (2005).
11. Haynes, B. F., Kelsoe, G., Harrison, S. C. & Kepler, T. B. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nature Biotechnol. 30, 423-433 (2012).
12. Mouquet, H. & Nussenzweig, M. C. Polyreactive antibodies in adaptive immune responses to viruses. Cell. Mol. Life Sci. 69, 1435-1445 (2012).
13. Scheid, J. F. et al. Broad diversity of neutralizing antibodies isolated frommemory B cells in HIV-infected individuals. Nature 458, 636-640 (2009).
14. Chen, W. et al. All known cross-reactive HIV-1 neutralizing antibodies are highly divergent from germline and their elicitation may require prolonged periods of time. AIDS Res. Human Retrovirol. 24, Abstract DA03-03 (2008).
15. Dimitrov, D. S. Therapeutic antibodies, vaccines and antibodyomes. MAbs 2, 347-356 (2010).
16. Ma, B. J. et al. Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog. 7, e1002200 (2011).
17. Pancera, M. et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 84, 8098-8110 (2010).
18. Xiao, X. et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 390, 404-409 (2009).
19. Alam, S. M. et al. Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. J. Virol. 85, 11725-11731 (2011).
20. Bonsignori, M. et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85, 9998-10009 (2011).
21. Mouquet, H. et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467, 591-595 (2010).
22. Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011).
23. Hoot, S. et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4-binding site bNAbs. PLoS Pathog. 9, e1003106 (2013).
24. Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 105, 7552-7557 (2008).
25. Richman, D. D., Wrin, T., Little, S. J. & Petropoulos, C. J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100, 4144-4149 (2003).
26. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
27. Corti, D. et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 5, e8805 (2010).
28. Gray, E. S. et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD41 T cell decline and high viral load during acute infection. J. Virol. 85, 4828-4840 (2011).
29. Klein, F. et al. Broad neutralization by a combination of antibodies recognizing the CD4binding site and a newconformational epitope on the HIV-1 envelope protein. J. Exp. Med. 209, 1469-1479 (2012).
30. Lynch, R. M. et al. The development of CD4 binding site antibodies during HIV-1 infection. J. Virol. 86, 7588-7595 (2012).
31. Moore, P. L., Gray, E. S. & Morris, L. Specificity of the autologous neutralizing antibody response. Curr. Opin. HIV AIDS 4, 358-363 (2009).
32. Moore, P. L. et al. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targetinga quaternary epitope including residues in the V2loop. J. Virol. 85, 3128-3141 (2011).
33. Tomaras,G.D. et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 85, 11502-11519 (2011).
34. Liao, H. X. et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J. Exp. Med. 208, 2237-2249 (2011).
35. Tomaras, G. D. et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82, 12449-12463 (2008).
36. Scheid, J. F. et al. A method for identification of HIV gp140 bindingmemory B cells in human blood. J. Immunol. Methods 343, 65-67 (2009).
37. Seaman,M.S. et al. Tiered categorizationof adiversepanel of HIV-1Envpseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439-1452 (2010).
38. Boyd,S.D. et al. Measurement andclinicalmonitoring ofhumanlymphocyte clonality by massively parallel VDJ pyrosequencing. Sci. Transl. Med. 1, 12ra23 (2009).
39. Bonsignori, M. et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J. Virol. 86, 4688-4692 (2012).
40. Haynes, B. F., Moody, M. A., Verkoczy, L., Kelsoe, G. & Alam, S. M. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum. Antibodies 14, 59-67 (2005).
41. Wardemann, H. et al. Predominant autoantibody production by early humanBcell precursors. Science 301, 1374-1377 (2003).
42. Shingai, M. et al. Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralizemultiple HIV-1strains. Proc.Natl Acad. Sci. USA 109, 19769-19774 (2012).
43. Alam, S. M. et al. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178, 4424-4435 (2007).
44. Malherbe, D. C. et al. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J. Virol. 85, 5262-5274 (2011).
45. Alam, S. M. et al. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 82, 115-125 (2008).
46. Montefiori, D. C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol.Chapter 12, Unit 12.11 (2005).
47. Larkin, M. A. et al. Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947-2948 (2007).
48. Zar, J. H. Biostatistical Analysis (Pearson, 1974).
49. Junier, T.& Zdobnov, E. M. The Newick utilities: high-throughput phylogenetic tree processing in the UNIX shell. Bioinformatics 26, 1669-1670 (2010).
50. Moir, S. et al. Normalization ofB cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J. Infect. Dis. 197, 572-579 (2008).
51. Liao, H. X. et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J. Virol. Methods 158, 171-179 (2009).
52. Liao, H. X. et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, 176-186 (2013).
53. André, S. et al. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J. Virol. 72, 1497-1503 (1998).
54. Liao, H. X. et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353, 268-282 (2006).
55. Montefiori, D. C. et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206, 431-441 (2012).
56. Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406-412 (2012).
57. Wolinsky, S. M. et al. Response: HIV-1 evolution and disease progression. Science 274, 1010-1011 (1996).
58. Kwong, P. D. et al. Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1). J. Biol. Chem. 274, 4115-4123 (1999).
59. Kwon, Y. D. et al. Unliganded HIV-1 gp120 core structures assumethe CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc. Natl Acad. Sci. USA 109, 5663-5668 (2012).
60. Bai, Y., Auperin, T. C.& Tong, L. The use of in situ proteolysis in the crystallization of murine CstF-77. Acta Crystallogr. F 63, 135-138 (2007).
61. Mandel, C. R., Gebauer, D., Zhang, H. & Tong, L. A serendipitous discovery that in situ proteolysis is essential for the crystallization of yeast CPSF-100 (Ydh1p). Acta Crystallogr. F 62, 1041-1045 (2006).
62. Otwinowski, Z. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307 (1997).
63. McCoy, A. J. et al.Phaser crystallographic software. J.Appl. Crystallogr.40, 658-674 (2007).
64. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50, 760-763 (1994).
65. Adams, P. D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D 58, 1948-1954 (2002).
66. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126-2132 (2004).
67. Davis, I. W. et al. MolProbity: all-atomcontacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35, W375-W383 (2007).
68. Lü tteke, T. & von der Lieth, C. W. pdb-care (PDB carbohydrate residue check): a program to support annotation of complex carbohydrate structures in PDB files. BMC Bioinformatics 5, 69 (2004).
69. Kabat, E. A., Wu, T. T., Gottesman, K. S. & Foeller, C. Sequences of Proteins of Immunological Interest 5th edn (DIANE publishing, 1991).
70. Krissinel, E.&Henrick, K. Inference ofmacromolecular assemblies fromcrystalline state. J. Mol. Biol. 372, 774-797 (2007).
71. DeLano, W. L. The PyMOL Molecular Graphics System http://www.pymol.org (DeLano Scientific, 2002).